When designing clinical trials for Huntington’s disease, first ask the experts

Progress in understanding the genetic mutation responsible for Huntington’s disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments. How best to design clinical trials in which HD patients are willing to participate and comply is a question faced by researchers.

Leave a Reply

Your email address will not be published. Required fields are marked *